The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806).
Jinji Yang
No relevant relationships to disclose
Ying Cheng
No relevant relationships to disclose
Mingfang Zhao
No relevant relationships to disclose
Qing Zhou
No relevant relationships to disclose
Hong hong Yan
No relevant relationships to disclose
Li Zhang
No relevant relationships to disclose
Yong Song
No relevant relationships to disclose
Jianhua Chen
No relevant relationships to disclose
Weineng Feng
No relevant relationships to disclose
Chong-Rui Xu
No relevant relationships to disclose
Yi Long Wu
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche; Sanofi
Research Funding - AstraZeneca